Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) Director Nancy Thornberry sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director directly owned 1,109 shares in the company, valued at $607,576.74. The trade was a 47.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ:VRTX traded up $2.25 during trading on Wednesday, hitting $536.45. 1,284,080 shares of the stock traded hands, compared to its average volume of 1,392,333. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The company has a fifty day moving average price of $522.31 and a two-hundred day moving average price of $484.43. Vertex Pharmaceuticals Incorporated has a 52-week low of $412.27 and a 52-week high of $568.67. The company has a market cap of $136.01 billion, a price-to-earnings ratio of 34.52, a P/E/G ratio of 2.85 and a beta of 0.28.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.80 EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $11,975,849,000. Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth approximately $1,509,651,000. Legal & General Group Plc purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $928,893,000. Bank of New York Mellon Corp purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $830,842,000. Finally, Deutsche Bank AG acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at $784,391,000. 90.96% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on VRTX. Truist Financial upped their price target on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Evercore boosted their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. TD Cowen upped their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research note on Tuesday, November 3rd. Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $596.44.
Get Our Latest Research Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
